Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
International Journal of Oncology|June 6, 2007
Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemiaBertil Uggla, Elisabet Tina, Hareth Nahi, et al.
European Journal of Haematology|December 1, 2010
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cellsDina Ali, Kerstin Jönsson-Videsäter, Stefan Deneberg, et al.
American Journal of Hematology|September 16, 2020
Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myelomaCharlotte Gran, Johan Liwing, Arnika Kathleen Wagner, et al.
Cytotherapy|August 28, 2010
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactorTolga Sutlu, Birgitta Stellan, Mari Gilljam, et al.
European Journal of Haematology|September 6, 2019
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?Charlotte Gran, Katarina Uttervall, Johanna Borg Bruchfeld, et al.
European Journal of Haematology|April 14, 2020
Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatmentGarbriel Afram, Charlotte Gran, Johanna Borg Bruchfeld, et al.
Leukemia Research|June 15, 2010
Constitutional inv(3) in myelodysplastic syndromesCaroline Gahrton, Hareth Nahi, Monika Jansson, et al.
European Journal of Haematology|October 15, 2013
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patientsJohan Lund, Katarina Uttervall, Johan Liwing, et al.
European Journal of Haematology|September 6, 2022
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of careGabriel Afram, Roza Chaireti, Katarina Uttervall, et al.
Plos One|February 14, 2019
Infectious complications and NK cell depletion following daratumumab treatment of Multiple MyelomaHareth Nahi, Michael Chrobok, Charlotte Gran, et al.
Pageof 11